The clinical test to evaluate the effective and safety dosage of dantrolene for the treatment of ventricular tachycardia in patients with heart disease - The clinical test to evaluate the effective and safety dosage of dantrolene for the treatment of ventricular tachycardia in patients with heart disease

Kobayash Shigeki0 个研究点目标入组 30 人开始时间: 2019年3月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients with acute or chronic heart failure and sustained ventricular tachycardia(SVT) and those with CPVT and ARVC complicated with SVT:
•1) age; from 20 to < 85 years old
•2) eligible for man and female
•3) Patients with heart failure (myocardial infarction, cardiac sarcoidosis, dilated cardiomyopathy, hypertrophic cardiomyopathy, CPVT, ARVC et al.), complicated with VT
•4) Patient who receive the treatment according to the guidelines of diagnosis and treatment of acute and chronic heart failure (JCS2017/JHFS2017) and the guidelines of drug treatment of arrhythmias (JCS2009)
•5) eligible for patients with and without ICD (CRTd)
•6) patients with sustained VT who are refractory to oral administration of amiodarone or intravenous infusion of amiodarone, and those with sustained VT who cannot undergo amiodarone medication because of its severe adverse event
•7) patiens who provided written informed consent before participating in the study and for whom regal representative gave informed consent

•1)patients with COPD and severe dysfunction of respiratory function
•2)patient diagnosed with myasthenia gravis
•3)patients with severe liver dysfunction
•4)history of allergy and hypersensitivity for dantrolene
•5)patients with severe valvular heart disease and severe HOCM
•6)cancer patients
•7)paients who primary investigator and investigators consider as unsuitable for the present study.

发起方

Kobayash Shigeki